PI3K Inhibitor Screening in 3D Brain Hydrogel Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current test systems for neurological disorders, particularly Alzheimer's disease, are inadequate, leading to high failure rates in clinical trials and a lack of suitable animal models, making it difficult to develop effective treatments and predict disease progression.
Innovation Solution
A brain-specific 3D cell culture system using hydrogels with distinct viscoelasticity to simulate physiological and pathological brain conditions, allowing for the identification and evaluation of PI3K inhibitors that reduce Aβ and pTau protein accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current test systems are used for neurological disorders, then testing can be performed, but the reliability of results is poor leading to high failure rates in clinical trials
Solution Approach 1:
The patent creates a copy of the human brain's extracellular matrix using hydrogels with specific viscoelastic properties that mimic physiological brain tissue. This artificial model allows testing of drug candidates in a system that replicates human brain conditions, improving reliability while avoiding the need for lengthy clinical trials and animal models
Solution Approach 2:
The patent modifies the physical parameters of the test system by controlling the viscoelasticity of hydrogels to match physiological brain tissue properties. This parameter optimization enables more accurate simulation of brain cell behavior and drug response, thereby improving test reliability and reducing clinical trial failures
2Ease of manufacture
If animal models are used for testing, then preclinical data can be collected, but the transferability of results to humans is poor
Solution Approach 1:
Instead of using animal models, the patent creates an artificial human brain tissue model using hydrogels that replicate the extracellular matrix properties. This human-relevant model allows direct collection of preclinical data that is transferable to human clinical trials, eliminating the species translation problem
Solution Approach 2:
The patent introduces a hydrogel-based extracellular matrix as an intermediary system between animal models and human clinical trials. This artificial matrix serves as a human-relevant test platform that bridges the gap, providing preclinical data with high transferability to human patients
3Measurement precision
If clinical trials are conducted on Alzheimer patients, then treatment effects can be evaluated, but the time required is too long (5-10 years)
Solution Approach 1:
The patent performs preliminary testing of drug candidates on brain cells cultured in physiological hydrogel matrices before advancing to clinical trials. This preliminary action in a human-relevant model allows early evaluation of treatment effects, reducing the time required for full clinical trials while maintaining measurement precision
Solution Approach 2:
The patent creates a simplified copy of the human brain environment using hydrogels that support brain cell culture. This artificial system enables rapid assessment of drug effects on human brain cells without requiring long-term clinical observation periods, significantly reducing trial time while preserving evaluation accuracy
4Loss of time
If healthy humans are used for testing, then early drug effects can be observed, but it is morally unacceptable and scientifically questionable
Solution Approach 1:
The patent creates an artificial human brain tissue model using hydrogels that replicates the physiological environment of human brain cells. This model allows observation of early drug effects on human brain tissue without requiring healthy human volunteers, eliminating ethical concerns while maintaining the ability to observe early treatment responses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the testing of drug candidates to effectively reduce Aβ and pTau protein concentrations, providing a reliable method to identify potential treatments for neurological disorders, including Alzheimer's disease, and potentially reversing pathological conditions.
Implementation Method 1
A brain-specific 3D cell culture system using hydrogels with distinct viscoelasticity to simulate physiological and pathological brain conditions
Data Source
Figure 1~2
Figure 3a~3b
Figure 4
AI summary
The invention refers to the field of neurodegenerative diseases including Alzheimer's Disease and a treatment thereof with a Benzoxazepine compound. Benzoxazepine compounds are e.g. known in the treatment of breast cancer and according to the use of the invention are a first therapeutic and prophylactic treatment for neurodegenerative diseases, including Alzheimer's Disease. The invention further relates to test systems for identifying, mapping, elaborating and evaluating said and further therapeutic and prophylactic uses of compounds of interest and/or other pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's Disease. (AD)